Apellis (APLS) and Sobi announced the European Medicines Agency has validated an indication extension application for Aspaveli for the ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...

Some cars have a tough time following up their predecessors. Others – such as the new Citroën C3 Aircross we're reviewing here – well, not so much. The previous-generation C3 Aircross had a ...

This is the all-new, second-generation Citroen C3 Aircross. Like the car it replaces, it’s essentially a slightly larger, raised version of the standard C3 supermini. It’s based on the same ...

Equipment levels are fairly sparse, but if you want a family runabout that’ll take seven people on occasion (two of them kids), then the C3 Aircross is a great addition to the market.

Equipment levels are fairly sparse, but if you want a family runabout that’ll take seven people on occasion (two of them kids), then the C3 Aircross is a great addition to the market.

ESC: updated contrast-induced nephropathy (CIN) prevention guidelines 2014. European Society of Urogenital Radiology: updated contrast media safety committee guidelines 2011. Define CIN and recognise ...

Pegcetacoplan: Apellis Pharmaceuticals Pegcetacoplan is a complement C3 inhibitor that has shown potential in treating Complement 3 Glomerulopathy (C3G) by targeting the dysregulated complement system ...

A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease worsening by 24% in people who also had diabetes. It also reduced the ...